Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review

FDA is evaluating clinical trial data that may suggest that patients taking Stalevo may be at an increased risk for developing prostate cancer.

Related Posts:

1. Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures
2. Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety
3. Zocor (simvastatin): increased risk of muscle injury with high doses
4. Asbestos Case Spotlight – Merlin Olsen vs Many
5. Weitz & Luxenberg Continues Efforts To Help People With Asbestos Cancers